ERBB2 and breast carcinoma: Bardou et al (2003) have found that PgR negativity is an indicator of poor prognosis in tamoxifen-treated women, and this is in accord with several reports that HER-2-positive patients (which are more likely to be PgR-negative) do less well on tamoxifen. However, the EBCTCG overview (Early Breast Cancer Trialists' Collaborative Group 2005) results do not indicate this differential effect in tamoxifen-treated women.